An ongoing dialogue on HIV/AIDS, infectious diseases,
January 8th, 2012
Journal Club: In Early HIV Infection, Little Reason to Delay Therapy
Every experienced HIV clinician will recognize the following new-patient scenario:
- At least one, but often several negative HIV antibody tests in the past, generally due to being in a “high risk” group.
- Recent non-specific viral-type illness that, in hindsight, was undoubtedly acute HIV infection, undiagnosed.
- Now completely recovered, but found to be newly HIV antibody positive.
- Physical exam normal, CD4 500 or higher, HIV RNA in the moderate range (10-100K).
How should patients like these be managed? Specifically, should antiretroviral therapy be started, or should they be observed?
Over in Journal of Infectious Diseases, the so-called Setpoint study — a randomized strategy trial — investigated whether a 36-week period of treatment would delay the need to go on continuous HIV therapy, compared with observation. After 130 of a planned 150 patients were enrolled, a Data Safety Monitoring Board elected to stop the study due to this key finding: “… the higher rate of progression to needing treatment in the Deferred Treatment group (50%) versus the Immediate Treatment (10%) group.”
Importantly, the findings would have been even stronger in favor of Immediate Treatment if more up-to-date CD4 thresholds (500 rather than 350) were used as a criterion to start therapy. (The study was designed in the mid 2000s.)
How do these results influence practice? As I’ve noted before, patients diagnosed with recently-acquired HIV infection should be counseled that even if treatment is deferred, there is a high likelihood they will need to start treatment relatively soon.
It’s also time to retire the “you may have 10 years before needing to go on therapy” counseling, something we might have been prone to do in the past to soften the blow of someone hearing that they’re HIV positive. This kind of delay is highly unlikely, and may be limited to the small fraction of patients who have very low HIV RNA and very high CD4s.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Subacute Sclerosing Panencephalitis after Measles Infection February 21, 2026A 7-year-old boy was brought to a hospital with a 3-month history of cognitive deterioration and seizures. He had contracted measles at 7 months of age while living in an area where the infection is endemic.
- AI-Enabled Precision-Education Systems — Transforming Lifelong Learning in Medicine February 21, 2026Trainees’ paths to safe, independent practice are variable. Artificial intelligence could help accelerate implementation of competency-based medical education to support individualized development.
- Revival of Ethionamide by Alpibectir February 19, 2026Ethionamide has been used to treat tuberculosis for decades, but dose-dependent toxic effects have limited its use. In this trial, alpibectir enabled the ethionamide dose to be reduced by two thirds.
- Peritoneal Coccidioidomycosis February 19, 2026A 23-year-old man presented with a 2-month history of unintentional weight loss and worsening abdominal pain and distention. He had recently moved to Arizona from a remote Pacific island.
- Reducing Tobacco Use Worldwide: Tobacco Cessation among Nondaily and Low-Intensity Smokers — Challenges and Opportunities in Latin America February 19, 2026In Latin America, though overall smoking rates have declined, nondaily and low-intensity smoking are increasingly common, and tobacco-cessation resources remain underdeveloped in many countries.
- Subacute Sclerosing Panencephalitis after Measles Infection February 21, 2026